Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

ClinicalTrials.gov ID: NCT01176240

Public ClinicalTrials.gov record NCT01176240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease. Droxidopa is being studied to determine the effects on blood pressure changes upon standing up (orthostatic challenge). Symptoms and activity measurements, including patient reported falls, will be evaluated to determine the effectiveness of the study drug. Symptoms of NOH may include any of the following: * Dizziness, light-headedness, feeling faint or feeling like you may blackout * Problems with vision (blurring, seeing spots, tunnel vision, etc.) * Weakness * Fatigue * Trouble concentrating * Head \& neck discomfort (the coat hanger syndrome) * Difficulty standing for a short time or a long time * Trouble walking for a short time or a long time The study duration is a maximum of approximately 14 weeks including up to 2 weeks for screening, up to 2 weeks for proper dose finding, followed by an 8 week treatment period and a follow-up visit after 2 weeks. A sufficient number of patients will be screened to allow approximately 211 randomized patients. An extension study is also available to continue treatment if determined appropriate by the study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling by invitation only.

Study identification

NCT ID
NCT01176240
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Chelsea Therapeutics
Industry
Enrollment
225 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2010 (Type not available)
Primary completion
Oct 2012 (Actual)
Completion
Nov 2012 (Actual)
Last update posted
May 20, 2014

2010 – 2012

United States locations

U.S. sites
60
U.S. states
22
U.S. cities
56
Facility City State ZIP Site status
Neurology Neurodiagnostic Lab Alabaster Alabama 35007 —
Neurological Physicians of Arizona Gilbert Arizona 85234 —
Xenoscience Phoenix Arizona 85004 —
Barrow Neurology Clinic Phoenix Arizona 85013 —
Banner Health Sun City Arizona 85351 —
Center for Neurosciences Tucson Arizona 85718 —
Northwest Neuro Specialists P.L.L.C. Tucson Arizona 85741 —
Caring Clinical Research Incorporated Laguna Hills California 92653 —
Hoag Memorial Hospital, Presbyterian Newport Beach California 92663 —
Neurosearch - Pasadena Pasadena California 91105 —
Alliance Clinical Research, LLC Poway California 92064 —
Neurosearch, Inc. Reseda California 91335 —
Neurosearch II, Inc. Ventura California 93003 —
Neurology Consultants Medical Group Whittier California 90606 —
Associated Neurologist of Southern Connecticut, PC Fairfield Connecticut 06824 —
Hartford Hospital Hartford Connecticut 06106 —
Eastern Connecticut Neurology Specialists Manchester Connecticut 06040 —
Parkinson's Disease & Movement Disorder Disoder Boca Raton Florida 33486 —
Pharmax Research Clinic, LLC Miami Florida 33126 —
Neurology Associates of Ormond Beach Ormond Beach Florida 32174 —
Neurostudies Inc. Port Charlotte Florida 33952 —
Parkinson's Disease Treatment Center of Southwest Florida Port Charlotte Florida 33980 —
Lovelace Scientific Research Sarasota Florida 34233 —
Tampa General University of South Florida Tampa Florida 33606 —
Vero Neurology Vero Beach Florida 32960 —
Premiere Research Institute West Palm Beach Florida 33407 —
Emory University Atlanta Georgia 30329 —
Neurology Specialists of Decatur Research Center Decatur Georgia 30033 —
Prism Research Group Rome Georgia 30165 —
Alexian Brothers Hospital Network Elk Grove Village Illinois 60007 —
Precise Clinical Research Topeka Kansas 66604 —
North Oaks Health System Hammond Louisiana 70403 —
Harvard Vanguard Medical Associates Boston Massachusetts 02215 —
Detroit Clinical Research Center Novi Michigan 48377 —
Northern Michigan Neurology Traverse City Michigan 49684 —
Gulf Coast Neurology Center, PLLC Ocean Springs Mississippi 39564 —
University of Nevada School of Medicine Las Vegas Nevada 89102 —
Wellness and Research Center Belvidere New Jersey 07823 —
AdvanceMed Research Lawrenceville New Jersey 08648 —
Shore Neurology Toms River New Jersey 08755 —
Upstate Clinical Research, LLC Albany New York 12205 —
David L. Kreitzman, M.D., PC Commack New York 11725 —
Kingston Neurological Associates Kingston New York 12401 —
Parker Jewish Institute For Health Care and Rehabilitation Foundation New Hyde Park New York 11040-1433 —
Beth Israel Medical Center New York New York 10003 —
New York University New York New York 10016 —
Neurological Care of CNY Syracuse New York 13210 —
Asheville Neurology Specialists, PA Asheville North Carolina 28806 —
Guilford Neurologic Associates Greensboro North Carolina 27405 —
Clinical Trials of America Inc Winston-Salem North Carolina 27103 —
Community Research Cincinnati Ohio 45227 —
Ohio State University Medical Center Columbus Ohio 43210 —
University of Toledo Toledo Ohio 43614 —
Movement Disorder Clinic of Oklahoma PLLC Tulsa Oklahoma 74136 —
Ilumina Clinical Associates Johnstown Pennsylvania 15904 —
Clinical Trials Research Services LLC Pittsburgh Pennsylvania 15206 —
UT Southwestern Medical Center at Dallas Dallas Texas 75390-9063 —
JM Neuroscience Research Salt Lake City Utah 84108 —
Neurological Associates, Inc. Richmond Virginia 23226 —
Sentara Neurology Specialists Virginia Beach Virginia 23456 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01176240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 20, 2014 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01176240 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →